| Homepage | Forward to a Friend | Make a Donation |
 |
| eLetter #658 | May 6, 2016 |
|
|
What's Behind the Heartbreaking Risk of Anti-Inflammatory Drugs
 Researches have known for more than a decade that the risk of heart disease and stroke increases when people take pain relievers. Now, scientists from the University of California, Davis have uncovered some of the reasons why these drugs can harm heart tissue.
Click here for more >>
|
|
Scleroderma Research Foundation (SRF) Presents Webinar on Improving Function of Hands and Face
The
SRF webinar series is designed for patients and others in the
scleroderma community to provide a greater understanding of the disease,
how to better manage its complications, and share what is being done to
find a cure. On Wednesday, May 11, Dr. Janet Poole, a
Professor in the Occupational Therapy Graduate Program at the University
of New Mexico will lead a session on improving function of the hands and face.
|
|
Video: Improving Your Sexuality
 The Federation of European Scleroderma Associations aisbl (FESCA), has released a series of videos that were recorded at the 4th Systemic Sclerosis World Congress earlier this year. The workshops cover a variety of different topics and features. This video discusses ways to improve your sexuality and other relationship questions.
Click here to watch the entire video >>
|
|
Traveling While Gluten Free - A Survival Guide
 Awareness of celiac disease may be on the rise but many places have never heard of it. Patience is required - both in explaining the issue and handling mistakes. Thankfully there are far more options available now than ever before.
Click here to read more >>
|
Clinical Trial Update
|
|
Systemic Scerosis Responds to Actemra in Early Trial
Interleukin (IL)-6 inhibition with tocilizumab (Actemra) may offer benefit in the treatment of systemic sclerosis, a phase II proof-of-concept study suggested. At week 48, the change in mean Rodnan skin score from baseline among patients receiving tocilizumab was -6.33 compared with a change of -2.77 among those given placebo, for a difference of -3.55 (95% CI -7.23 to 0.12, P=0.06), according to Christopher Denton, MD, of University College London.
Click here for more >>
|
|
|
|
|
Disclaimer: The Scleroderma Foundation in no way
endorses any drugs, treatments, clinical trials, or studies reported in the eLetter. Information is
provided to keep the readers informed. Because the manifestations and severity of scleroderma vary among individuals, personalized medical management is essential. Therefore, it is strongly recommended that all drugs and treatments be discussed with the reader’s physician(s) for proper evaluation and treatment.
|
 |
|
